Vet-Stem Inc. announced that over 8000 animals have now been treated with Vet-Stem cell therapy.
Vet-Stem began providing stem cells to veterinarians in 2004 and has now provided stem cells for the treatment of over 8,000 animals. Vet-Stem was the first company to introduce rapid turnaround stem cell services in the US.
After providing stem cells for thousands of horses, Vet-Stem pioneered stem cell therapy in dogs and cats and is now the world leader in Regenerative Veterinary Medicine. The rapid adoption of stem cell therapy by equine veterinarians and horse owners provided a springboard for use in small animal veterinary
Discarded fallopian tubes from hysterectomies could be a good source of donor stem cells, say researchers.
Work shows they are an abundant source of the immature cells that have the potential to become a variety of the body’s tissues, like muscle and bone.
The discovery offers another “ethical” route to creating stem cell treatments for diseases like arthritis without using embryos.
The findings are published in The Journal of Translational Medicine.
Experts have already shown that getting mesenchymal stem cells from umbilical cords, menstrual blood, teeth and fat tissue is viable.
The latest work by a Brazilian team from the University of São
Stem-cell firm BioTime said this week that it will open a subsidiary in China called BioTime Asia to expand its stem cell therapeutics and research tools to the Asian market.
BioTime Asia will be based at the Nanshan Memorial Medical Institute, or NSMMI, and will clinically develop and market therapeutic stem cell products in China and market stem cell research products in China and other Asian countries (…)
Cord Blood Registry (CBR) is the exclusive partner for a growing number of clinical researchers focusing on the use of a child’s own cord blood stem cells to help treat pediatric brain injury and acquired hearing loss. To ensure consistency in cord blood stem cell processing, storage and release for infusion, three separate trials have included CBR in their FDA-authorized protocol—including two at the University of Texas Health Science Center at Houston (UTHealth) working in partnership with Children’s Memorial Hermann Hospital, and a third at Georgia Health Sciences University, home of the Medical College of Georgia (MCG). This makes
In the first human study of its kind, researchers found that using stem cells to re-grow craniofacial tissues—mainly bone—proved quicker, more effective and less invasive than traditional bone regeneration treatments.
Researchers from the University of Michigan School of Dentistry and the Michigan Center for Oral Health Research partnered with Ann Arbor-based Aastrom Biosciences Inc. in the clinical trial, which involved 24 patients who required jawbone reconstruction after tooth removal.
Patients either received experimental tissue repair cells or traditional guided bone regeneration therapy. The tissue repair cells, called ixmyelocel-T, are under development at Aastrom, which is a U-M spinout company.